# Microbiotica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microbiotica

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.microbiotica.com
- Total disclosed funding: $121M
- Latest round: Series C (Oct 16, 2026)
- Investors on record: 9

## About

Microbiotica Limited is a biotechnology company focused on developing clinic-ready live biotherapeutic products for therapeutic applications in immuno-oncology and inflammatory bowel disease, aiming to transform advanced microbiome science into effective medicines.Founded in 2016 and headquartered in Cambridge, UK, Microbiotica Limited specializes in live biotherapeutics targeting various health conditions. The firm has successfully completed 3 deals, with the most recent funding round being a Series B that raised GBP 51.18 million on March 4, 2022. Notable investors in this round include British Patient Capital, Cambridge Innovation Capital, Flerie Invest, Longview Innovation, Seventure Partners, and Tencent Investment. The company was co-founded by Gordon Dougan and Trevor Lawley, and its current CEO is Hans Rittinghausen.Microbiotica specializes in the development of clinic-ready live biotherapeutic products (LBPs) that are orally delivered and composed of highly-defined bacterial strains. These products are specifically designed for therapeutic applications in immuno-oncology and inflammatory bowel disease. The company aims to translate advanced microbiome science into transformative medicines that address unmet medical needs, with a focus on improving patient outcomes. Microbiotica’s offerings are primarily targeted at healthcare providers and research institutions, which utilize these therapies to treat patients suffering from conditions such as ulcerative colitis and other related disorders. The geographical markets for these products include the United States and the European Union, where there is a growing demand for innovative biopharmaceutical solutions.Microbiotica’s revenue model is centered around partnerships with healthcare providers and research institutions, where products are typically supplied through direct sales and clinical collaborations. The company conducts transactions that involve bulk orders of its biotherapeutic products to hospitals and clinics, facilitating access to advanced treatments for patients. Furthermore, Microbiotica engages in strategic partnerships with other biopharmaceutical firms to co-develop or co-market specific products, enhancing its market reach and revenue potential. Specific pricing plans are not disclosed, but the organization’s flagship products are positioned to align with current market standards for advanced biopharmaceutical therapies.In March 2022, Microbiotica Limited raised GBP 51.18 million in Series B funding, co-led by new investors Flerie Invest and Tencent Investment, with participation from British Patient Capital and returning investors. The funding will be utilized to expand the company's discovery pipeline of biomarkers in new diseases. Microbiotica plans to innovate new products and possibly explore expansion into new geographic regions, although specific markets have not been disclosed.

## Funding rounds

- Series C, Oct 16, 2026, $48M — British Business Bank, Cambridge Innovation Capital, Flerie Invest, IP Group, Seventure Partners, Tencent
- Series B, Mar 4, 2022, $68M — Seventure Partners, Longview Innovation, Tencent Investment, Cambridge Innovation Capital, Flerie Invest, British Patient Capital
- Seed, Oct 19, 2018, $5.2M — Seventure Partners

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Seed, Series B, Series C
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series B
- Tencent Investment — Series B
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Series B, Series C
- Flerie Invest (https://capitalatlas.ai/funds/flerie-invest) — Series B, Series C
- British Patient Capital — Series B
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series C
- IP Group — Series C
- Tencent — Series C